JPMorgan Chase & Co. increased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,616,694 shares of the medical technology company’s stock after acquiring an additional 1,419,730 shares during the quarter. JPMorgan Chase & Co.’s holdings in Medtronic were worth $5,150,420,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of MDT. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the 4th quarter valued at about $27,000. Anfield Capital Management LLC boosted its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the 4th quarter valued at about $29,000. GoalVest Advisory LLC purchased a new position in Medtronic in the fourth quarter worth approximately $29,000. Finally, Imprint Wealth LLC purchased a new position in Medtronic in the third quarter worth approximately $31,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Trending Headlines about Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic’s fiscal Q4 results beat revenue expectations and showed continued year-over-year growth, while management signaled confidence in the company’s FY26/FY27 growth outlook and new product platforms. Medtronic (MDT) Climbs 5.7% on Stellar Q4
- Positive Sentiment: BTIG upgraded Medtronic to Buy with a $90 target, citing a strong revenue beat and improving organic growth, while other firms such as TD Cowen and RBC reaffirmed bullish ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
- Positive Sentiment: Medtronic expanded its relationship with Retia Medical to distribute the Argos Cardiac Output Monitor across Western Europe, adding to its cardiovascular portfolio and international reach. Retia Medical Expands Distribution of Argos® Cardiac Output Monitor to Western Europe with Medtronic
- Positive Sentiment: Medtronic also announced a higher quarterly dividend, signaling confidence in cash generation and shareholder returns. Medtronic (MDT) Climbs 5.7% on Stellar Q4
- Neutral Sentiment: Several brokerages lowered price targets after earnings, but most still kept Buy/Outperform or Hold/Neutral ratings, suggesting a reset in expectations rather than a major change in long-term views. Rothschild & Co Redburn cuts Medtronic price target
- Neutral Sentiment: Analyst roundups highlighted that Wall Street’s average recommendation remains Buy, but those consensus ratings are often viewed as overly optimistic and not always predictive. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
- Negative Sentiment: Medtronic is still dealing with ongoing cardiovascular device recalls tied to potential sterile barrier issues, which could weigh on investor sentiment and create some execution risk. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on MDT
Medtronic Trading Down 0.0%
MDT opened at $81.66 on Monday. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The business has a fifty day simple moving average of $81.46 and a 200-day simple moving average of $92.01. The firm has a market cap of $104.84 billion, a P/E ratio of 21.89, a P/E/G ratio of 1.99 and a beta of 0.58. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The business had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same period last year, the business posted $1.62 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts expect that Medtronic PLC will post 5.94 earnings per share for the current year.
Medtronic Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be given a dividend of $0.72 per share. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. The ex-dividend date is Friday, June 26th. Medtronic’s dividend payout ratio (DPR) is 76.14%.
About Medtronic
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Articles
- Five stocks we like better than Medtronic
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
